Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AURA vs TERN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TERN Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–0 Matrix Metrics)

TERN Overall Winner 6-Pillar Tally: AURA 1 – 3 TERN (2 Tie) Matrix Metrics: AURA 0 – 5 TERN

As of Nov 16, 2026, Terns Pharmaceuticals, Inc. (TERN) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas TERN carries 51.9/100 (HOLD) at $52.95 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AURA vs TERN
AURA NASDAQ
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 75% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 8.0 Fund 39.0 Flow 71.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.3 · SMA20: $6.66 · SMA50: $6.54
TERN NASDAQ Head-to-Head Winner
Terns Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$52.95
+0.04% 1D
Market Cap $6.1B
TTM Revenue $1.0M
Forward P/E N/M
Beta / 30D Vol 0.07β · 2% Vol
Unified Composite Score
51.9 / 100 HOLD
Tech 40.0 Fund 42.0 Flow 60.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.7% over 20 days), RSI 75
RSI-14: 74.7 · SMA20: $52.78 · SMA50: $49.21

6-Pillar Scorecard Institutional Category Breakdown (AURA 1 – 3 TERN)

Columns: Metric · AURA · TERN
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale TERN
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.0M
Market Cap $728.6M $6.1B
3. Profitability & Quality TERN
Gross Margin N/A 100.0%
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -61.7% -14.2%
4. Balance Sheet & Cash Flow AURA
Cash Generation (TTM) -$110M -$110M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $26M Net Cash $8.96 Book/Sh · -14.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TERN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 160.1% (22nd %ile) 0.6% (<1st %ile)
Put/Call OI Skew N/A 0.21x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AURA (0) vs TERN (5)
Institutional Metric AURA TERN Criterion Row Edge
Market Capitalization
Scale
$728.6M $6.1B Larger Scale TERN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-61.7% -14.2% Higher ROE TERN
52-Week Range Position
Momentum
52% ($5–$10) 100% ($3–$53) Stronger Trend TERN
Beta / 30D Volatility
Risk Regime
0.92β · 75% Vol 0.07β · 2% Vol Lower Realized Risk TERN
Unified Institutional Score
Composite Signal
31.1 / 100 (SELL) 51.9 / 100 (HOLD) Higher Composite TERN
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$110M ($26M Net Cash) -$110M EBITDA ($8.96 Book/Sh · -14.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AURA +27.24 pp
AURA: +27.68% · TERN: +0.44%
3M Horizon TERN +1.8 pp
AURA: +42.01% · TERN: +43.81%
6M Horizon TERN +104.44 pp
AURA: +50.99% · TERN: +155.43%
1Y Horizon TERN +104.44 pp
AURA: +50.99% · TERN: +155.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AURA vs TERN. Trailing 12-month operating profitability (AURA 0.0% vs TERN 0.0%) and valuation multiples (AURA N/M vs TERN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-61.7% · N/M
TERN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.0M
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-14.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AURA CONSOLIDATION
135d in phase · OBV DISTRIBUTION
Current IV 160.1%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TERN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.6%
IV Percentile <1st %ile
Put/Call OI Skew 0.21x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TERN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $728.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TERN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AURA vs TERN Key Questions & Quantitative Answers

As of Nov 16, 2026, Terns Pharmaceuticals, Inc. (TERN) is the stronger overall head-to-head candidate over Aura Biosciences, Inc. (AURA) in the Tradestie Institutional Equity Comparison Engine, winning 5–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). AURA carries a Unified Composite Score of 31.1/100 (SELL) at $7.21 (N/M Forward P/E, 0.0% operating margin), whereas TERN carries 51.9/100 (HOLD) at $52.95 (N/M Forward P/E, 0.0% operating margin). Technically, AURA sits in a Neutral phase (RSI 58.3, CONSOLIDATION options structure) and TERN sits in a Markup phase (RSI 74.7, UNCLASSIFIED options structure).

TERN leads the Growth & Scale pillar: AURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TERN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, AURA generates N/A in USD-normalized revenue versus $1.0M for TERN. In operating R&D and SG&A reinvestment, AURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TERN.

AURA and TERN trade at balanced relative valuation multiples. AURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TERN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AURA (-61.7% ROE) versus TERN (-14.2% ROE) capital efficiency.

In options market volatility and institutional positioning, AURA carries 160.1% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 75% Vol realized risk). By comparison, TERN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.07β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.